One Invesque Insider Raised Their Stake In The Previous Year
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Invesque
The CEO & Director Adlai Chester made the biggest insider purchase in the last 12 months. That single transaction was for CA$860k worth of shares at a price of CA$0.051 each. We do like to see buying, but this purchase was made at well below the current price of CA$0.11. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
Invesque is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From looking at our data, insiders own CA$1.9m worth of Invesque stock, about 1.9% of the company. I generally like to see higher levels of ownership.
It doesn't really mean much that no insider has traded Invesque shares in the last quarter. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Invesque stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Our analysis shows 3 warning signs for Invesque (2 are a bit concerning!) and we strongly recommend you look at them before investing.
Of course Invesque may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
MCAN Mortgage Second Quarter 2025 Earnings: Beats Expectations
MCAN Mortgage (TSE:MKP) Second Quarter 2025 Results Key Financial Results Revenue: CA$60.8m (up 81% from 2Q 2024). Net income: CA$20.2m (up 2.2% from 2Q 2024). Profit margin: 33% (down from 59% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: CA$0.51. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period MCAN Mortgage Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) also surpassed analyst estimates by 6.3%. Looking ahead, revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Diversified Financial industry in North America. Performance of the market in Canada. The company's shares are up 4.0% from a week ago. Risk Analysis Be aware that MCAN Mortgage is showing 3 warning signs in our investment analysis and 1 of those doesn't sit too well with us... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Keyera Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Keyera (TSE:KEY) Second Quarter 2025 Results Key Financial Results Revenue: CA$1.61b (down 6.3% from 2Q 2024). Net income: CA$126.5m (down 11% from 2Q 2024). Profit margin: 7.9% (down from 8.3% in 2Q 2024). The decrease in margin was driven by lower revenue. EPS: CA$0.55 (down from CA$0.62 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Keyera EPS Beats Expectations, Revenues Fall Short Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 53%. Looking ahead, revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Oil and Gas industry in Canada. Performance of the Canadian Oil and Gas industry. The company's shares are down 2.1% from a week ago. Risk Analysis Before you take the next step you should know about the 1 warning sign for Keyera that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 hours ago
- Yahoo
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see GSK plc (LON:GSK) is about to trade ex-dividend in the next four days. The ex-dividend date is commonly two business days before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Accordingly, GSK investors that purchase the stock on or after the 14th of August will not receive the dividend, which will be paid on the 9th of October. The company's next dividend payment will be UK£0.16 per share. Last year, in total, the company distributed UK£0.61 to shareholders. Calculating the last year's worth of payments shows that GSK has a trailing yield of 4.4% on the current share price of UK£13.955. If you buy this business for its dividend, you should have an idea of whether GSK's dividend is reliable and sustainable. So we need to investigate whether GSK can afford its dividend, and if the dividend could grow. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. It paid out 75% of its earnings as dividends last year, which is not unreasonable, but limits reinvestment in the business and leaves the dividend vulnerable to a business downturn. It could become a concern if earnings started to decline. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. Dividends consumed 51% of the company's free cash flow last year, which is within a normal range for most dividend-paying organisations. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously. Check out our latest analysis for GSK Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Have Earnings And Dividends Been Growing? When earnings decline, dividend companies become much harder to analyse and own safely. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. With that in mind, we're discomforted by GSK's 6.3% per annum decline in earnings in the past five years. When earnings per share fall, the maximum amount of dividends that can be paid also falls. Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. GSK's dividend payments per share have declined at 4.8% per year on average over the past 10 years, which is uninspiring. While it's not great that earnings and dividends per share have fallen in recent years, we're encouraged by the fact that management has trimmed the dividend rather than risk over-committing the company in a risky attempt to maintain yields to shareholders. The Bottom Line Should investors buy GSK for the upcoming dividend? While earnings per share are shrinking, it's encouraging to see that at least GSK's dividend appears sustainable, with earnings and cashflow payout ratios that are within reasonable bounds. It's not that we think GSK is a bad company, but these characteristics don't generally lead to outstanding dividend performance. With that being said, if you're still considering GSK as an investment, you'll find it beneficial to know what risks this stock is facing. For example - GSK has 3 warning signs we think you should be aware of. A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
